GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuneering Corp (NAS:IMRX) » Definitions » Total Equity

Immuneering (Immuneering) Total Equity : $78.72 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immuneering Total Equity?

Immuneering's total equity for the quarter that ended in Mar. 2024 was $78.72 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Immuneering Total Equity Historical Data

The historical data trend for Immuneering's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuneering Total Equity Chart

Immuneering Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
-6.53 -22.48 155.98 109.85 90.58

Immuneering Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.79 115.10 104.02 90.58 78.72

Immuneering Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Immuneering's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=102.585-12.008
=90.58

Immuneering's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=87.983-9.26
=78.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immuneering Total Equity Related Terms

Thank you for viewing the detailed overview of Immuneering's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuneering (Immuneering) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, Second Floor, Cambridge, MA, USA, 02142
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Harold Eugene Brakewood officer: Chief Business Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Leah R Neufeld officer: Chief People Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Mallory Morales officer: Vice President, Finance C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Brett Matthew Hall officer: Chief Scientific Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Michael Bookman officer: General Counsel and Secretary C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Biren Amin officer: CFO, Treasurer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Benjamin J. Zeskind director, 10 percent owner, officer: President and CEO C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Scott Barrett officer: Chief Medical Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Ann E Berman director 255 STATE STREET, BOSTON MA 02109

Immuneering (Immuneering) Headlines

From GuruFocus

Immuneering Announces Participation in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-09-2022

Immuneering Announces Participation in March Investor Conferences

By sperokesalga sperokesalga 02-28-2023

Immuneering Announces Participation in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-29-2022